SG11201408251SA - A pharmaceutical composition containing nicotinic acid and/or nicotinamide and/or tryptophan for positively influencing the intestinal microbiota - Google Patents
A pharmaceutical composition containing nicotinic acid and/or nicotinamide and/or tryptophan for positively influencing the intestinal microbiotaInfo
- Publication number
- SG11201408251SA SG11201408251SA SG11201408251SA SG11201408251SA SG11201408251SA SG 11201408251S A SG11201408251S A SG 11201408251SA SG 11201408251S A SG11201408251S A SG 11201408251SA SG 11201408251S A SG11201408251S A SG 11201408251SA SG 11201408251S A SG11201408251S A SG 11201408251SA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- pharmaceutical composition
- nicotinamide
- composition containing
- nicotinic acid
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/05—Dipeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0031—Rectum, anus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
- A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
- A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Abstract
(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 19 December 2013 (19.12.2013) WIPOIPCT (10) International Publication Number WO 2013/186355 A1 (51) International Patent Classification: A61K31/405 (2006.01) A61P 35/00 (2006.01) A61K31/455 (2006.01) 46 IK 9/00 (2006.01) (21) International Application Number: PCT/EP2013/062363 (22) International Filing Date: 14 June 2013 (14.06.2013) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 10 2012 011 890.2 15 June 2012 (15.06.2012) DE (71) Applicant: CONARIS RESEARCH INSTITUTE AG [DE/DE]; Schauenburgerstr. 116, 24118 Kiel (DE). (72) Inventors: WAETZIG, Georg; Elfriede-Dietrich-Str. 77, 24106 Kiel (DE). SEEGERT, Dirk; Paul-Schroder-Str. 30, 24229 Danischenhagen (DE). (74) Agents: DORFF, Gemot et al.; Eisenfuhr, Speiser & Part ner, P. O. Box 10 60 78, 28060 Bremen (DE). (81) Designated States (unless otherwise indicated, for every kind of national protection available)'. AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available)'. ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: — with international search report (Art. 21(3)) (54) Title: A PHARMACEUTICAL COMPOSITION CONTAINING NICOTINIC ACID AND/OR NICOTINAMIDE AND/OR TRYPTOPHAN FOR POSITIVELY INFLUENCING THE INTESTINAL MICROBIOTA m 00 i-H en i-H o CJ o & Fig. 1 *&~Ace2*y / Vehicle ce2 'y + Vehicle -*-Ace2\"'y Vehicle -o-4ce2^' MAM HaM ce2~V NAM Days after DSS e »&Mce2\" ;y Trp+ f ss ^StAce2^ Trp+ M >\" Ace2 ^ Control \ Mce2-''v Control £ Days after DSS Days after DSS (57) Abstract: The present invention relates to a new pharmaceutical composition containing nicotinic acid, nicotinamide, tryptophanor related compounds for posit ively influencing the intestinal microbiota. In certain em bodiments,the pharmaceutical composition is partially or entirely released into the small intestine or large intestine.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102012011890 | 2012-06-15 | ||
| PCT/EP2013/062363 WO2013186355A1 (en) | 2012-06-15 | 2013-06-14 | A pharmaceutical composition containing nicotinic acid and/or nicotinamide and/or tryptophan for positively influencing the intestinal microbiota |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201408251SA true SG11201408251SA (en) | 2015-01-29 |
Family
ID=47002494
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201408251SA SG11201408251SA (en) | 2012-06-15 | 2013-06-14 | A pharmaceutical composition containing nicotinic acid and/or nicotinamide and/or tryptophan for positively influencing the intestinal microbiota |
Country Status (32)
| Country | Link |
|---|---|
| US (2) | US10426765B2 (en) |
| EP (2) | EP3831379A1 (en) |
| JP (3) | JP6855165B2 (en) |
| KR (2) | KR20150021071A (en) |
| CN (2) | CN108273064A (en) |
| AR (1) | AR091465A1 (en) |
| AU (1) | AU2013276451B2 (en) |
| BR (1) | BR112014030835B1 (en) |
| CA (1) | CA2876540C (en) |
| CY (1) | CY1123999T1 (en) |
| DK (1) | DK2861229T3 (en) |
| ES (1) | ES2859758T3 (en) |
| HK (1) | HK1204972A1 (en) |
| HR (1) | HRP20210090T1 (en) |
| HU (1) | HUE053359T2 (en) |
| IL (1) | IL236205B (en) |
| IN (1) | IN2014DN10260A (en) |
| JO (1) | JO3578B1 (en) |
| LT (1) | LT2861229T (en) |
| MX (1) | MX370795B (en) |
| NZ (1) | NZ702297A (en) |
| PH (1) | PH12014502744A1 (en) |
| PL (1) | PL2861229T3 (en) |
| PT (1) | PT2861229T (en) |
| RS (1) | RS61288B1 (en) |
| RU (1) | RU2657797C2 (en) |
| SA (1) | SA113340643B1 (en) |
| SG (1) | SG11201408251SA (en) |
| SI (1) | SI2861229T1 (en) |
| TW (1) | TWI624260B (en) |
| WO (1) | WO2013186355A1 (en) |
| ZA (1) | ZA201408922B (en) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013186355A1 (en) | 2012-06-15 | 2013-12-19 | Conaris Research Institute Ag | A pharmaceutical composition containing nicotinic acid and/or nicotinamide and/or tryptophan for positively influencing the intestinal microbiota |
| KR102294405B1 (en) * | 2013-06-05 | 2021-08-25 | 더 유니버시티 오브 브리티쉬 콜롬비아 | Anti-fibrogenic compounds, methods and uses thereof |
| EP3007680B1 (en) * | 2013-06-14 | 2020-02-19 | CONARIS research institute AG | Extended release nicotinamide formulation |
| DK3079675T3 (en) | 2013-12-13 | 2020-04-20 | Conaris Res Institute Ag | Pharmaceutical composition containing nicotinic acid and / or nicotinamide for use in beneficial effect of blood lipid levels by modifying the gut microbiota |
| CN105813644B (en) | 2013-12-13 | 2020-07-10 | 康纳里斯研究院股份公司 | Pharmaceutical composition for beneficially influencing the intestinal microbiota and/or treating gastrointestinal inflammation |
| EP2884282A1 (en) | 2013-12-13 | 2015-06-17 | CONARIS research institute AG | Use of tryptophan as a biomarker for patient selection, dosing and therapy monitoring for pharmaceutical compositions targeting the intestinal microbiota in diseases featuring tryptophan deficiency |
| EP3107553B1 (en) * | 2014-02-18 | 2021-12-01 | Universitätsklinikum Jena | Methods and compositions for intestinal microenvironment transfer |
| JP6446065B2 (en) * | 2014-05-12 | 2018-12-26 | ユニリーバー・ナームローゼ・ベンノートシヤープ | Niacinamide for inducing the formation of antimicrobial peptides |
| CN105287561A (en) * | 2015-11-25 | 2016-02-03 | 上海交通大学医学院附属瑞金医院 | Medicinal composition for treating ulcerative colitis |
| KR20220137150A (en) * | 2016-04-14 | 2022-10-11 | 크로마덱스 아이엔씨. | Use of nicotinamide riboside, nicotinic acid riboside, nicotinamide mononucleotide, and nicotinoyl compound derivatives in infant formula |
| US10874617B2 (en) | 2016-04-19 | 2020-12-29 | Ferring B.V. | Oral pharmaceutical compositions of mesalazine |
| US11622938B2 (en) | 2016-04-19 | 2023-04-11 | Conaris Research Institute Ag | Oral pharmaceutical compositions of nicotinamide |
| CN109718234A (en) * | 2017-10-31 | 2019-05-07 | 中国农业大学 | L-Trp is alleviating the application in intestinal inflammation and barrier function disorder |
| CN108935981A (en) * | 2018-06-05 | 2018-12-07 | 西北农林科技大学 | Perinatal period milch goat adds influence and its mechanism of the niacinamide to lamb glycolipid metabolism |
| WO2020166527A1 (en) * | 2019-02-12 | 2020-08-20 | めぐみ 田中 | Food or beverage for babies and infants, method for improving intestinal environment of baby or infant, and method for enhancing immunity of baby or infant |
| US20220175724A1 (en) * | 2019-03-28 | 2022-06-09 | Tohoku University | Prophylactic or Therapeutic Agent for Cancer |
| CN113398130A (en) * | 2020-03-16 | 2021-09-17 | 广州市妇女儿童医疗中心（广州市妇幼保健院、广州市儿童医院、广州市妇婴医院、广州市妇幼保健计划生育服务中心） | Use of nicotinamide for the prevention and treatment of gastrointestinal disorders |
| WO2022112489A1 (en) * | 2020-11-27 | 2022-06-02 | Conaris Research Institute Ag | Nicotinamide, nicotinamide precursors and nicotinamide metabolites and compositions thereof for reducing the time to resolution of symptoms in patients with covid-19 and other viral infections |
| JPWO2023002939A1 (en) * | 2021-07-19 | 2023-01-26 | ||
| WO2023187003A1 (en) * | 2022-03-30 | 2023-10-05 | Conaris Research Institute Ag | Composition comprising nicotinamide, nicotinamide precursors, nicotinamide metabolites or combinations thereof for preventing or reducing one or more post-acute symptoms of infectious diseases |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6129930A (en) | 1993-09-20 | 2000-10-10 | Bova; David J. | Methods and sustained release nicotinic acid compositions for treating hyperlipidemia at night |
| DE19524928A1 (en) * | 1995-07-08 | 1997-01-09 | Basf Ag | Process for the rectification of mixtures of high-boiling air and / or temperature sensitive substances, which require a high separation performance, in a fine vacuum, as well as columns suitable for this process |
| US5846983A (en) * | 1996-02-09 | 1998-12-08 | Mayo Foundation For Medical Education And Research | Colonic delivery of nicotine to treat inflammatory bowel disease |
| US5736532A (en) * | 1996-02-14 | 1998-04-07 | Furda; Ivan | Multifunctional fat absorption and blood cholesterol reducing formulation comprising chitosan |
| GB9614902D0 (en) * | 1996-07-16 | 1996-09-04 | Rhodes John | Sustained release composition |
| KR20010102963A (en) * | 1998-12-23 | 2001-11-17 | 윌리암스 로저 에이 | Combinations of ileal bile acid transport inhibitors and nicotinic acid derivatives for cardiovascular indications |
| US6713057B1 (en) | 1999-02-24 | 2004-03-30 | The Johns Hopkins University | Compositions and methods for modulating serum cholesterol |
| GB0015242D0 (en) | 2000-06-22 | 2000-08-16 | Nycomed Amersham Plc | Stabiliser for radiopharmaceuticals |
| AU2001278699A1 (en) | 2000-08-08 | 2002-02-18 | Shionogi And Co., Ltd. | Inflammatory cytokine production inhibitors |
| US20040185097A1 (en) | 2003-01-31 | 2004-09-23 | Glenmark Pharmaceuticals Ltd. | Controlled release modifying complex and pharmaceutical compositions thereof |
| US7417037B2 (en) | 2004-01-20 | 2008-08-26 | The Board Of Regents Of The University Of Oklahoma | Compositions and methods of treatment for inflammatory diseases |
| US20060264409A1 (en) | 2004-01-20 | 2006-11-23 | Harty Richard F | Compositions and methods of treatment for inflammatory diseases |
| US7326809B2 (en) | 2004-05-27 | 2008-02-05 | Antibe Therapeutics Inc. | Salts of 4- or 5-aminosalicylic acid |
| CA2581764A1 (en) * | 2004-09-27 | 2006-04-06 | Sigmoid Biotechnologies Limited | Minicapsule formulations |
| EP1920770A4 (en) | 2005-07-01 | 2010-09-29 | Ajinomoto Kk | Therapeutic agent for inflammatory bowel disease and tnf- alpha production inhibitor |
| EP2026651B1 (en) * | 2006-03-08 | 2013-04-17 | Cortria Corporation | Combination therapy with non-selective cox inhibitors to prevent cox-related gastric injuries |
| ITMI20061932A1 (en) | 2006-10-09 | 2008-04-10 | Carlo Ghisalberti | CHARGE TRANSFER COMPLEXES FOR MEDICAL USE |
| EP1935422A1 (en) * | 2006-12-20 | 2008-06-25 | PEJO Iserlohn Heilmittel-und Diät-GmbH & Co.KG | Pharmaceutical composition comprising nicotinamide or nicotinic acid |
| EP2214518A4 (en) * | 2007-10-19 | 2011-06-29 | Joel D Pardee | Metabolic enhancement therapy |
| US20110104282A1 (en) * | 2008-04-25 | 2011-05-05 | Karolinska Institutet Innovations Ab | New Therapy of Treatment of the Irritable Bowel Syndrome |
| US20100015220A1 (en) * | 2008-05-20 | 2010-01-21 | Wetterau John R | Niacin and nsaid combination therapy |
| KR20110011643A (en) * | 2008-06-02 | 2011-02-08 | 닥터 레디스 레보러터리즈 리미티드 | Modified release niacin formulations |
| JP5740306B2 (en) | 2008-10-03 | 2015-06-24 | ドクトル ファルク ファルマ ゲーエムベーハー | Compositions and methods for treating bowel disease using mesalamine granules |
| JP2011121889A (en) | 2009-12-09 | 2011-06-23 | En Otsuka Pharmaceutical Co Ltd | Amino acid composition for inflammatory bowel disease |
| JP2012102054A (en) | 2010-11-11 | 2012-05-31 | Kyodo Milk Industry Co Ltd | In-intestine polyamine fortifier |
| WO2012090224A1 (en) | 2010-12-29 | 2012-07-05 | Nutracryst Therapeutics Private Limited | Novel cocrystals / molecular salts of mesalamine to be used as improved anti-inflammatory drug |
| WO2013186355A1 (en) | 2012-06-15 | 2013-12-19 | Conaris Research Institute Ag | A pharmaceutical composition containing nicotinic acid and/or nicotinamide and/or tryptophan for positively influencing the intestinal microbiota |
| EP3007680B1 (en) | 2013-06-14 | 2020-02-19 | CONARIS research institute AG | Extended release nicotinamide formulation |
| US11622938B2 (en) | 2016-04-19 | 2023-04-11 | Conaris Research Institute Ag | Oral pharmaceutical compositions of nicotinamide |
-
2013
- 2013-06-14 WO PCT/EP2013/062363 patent/WO2013186355A1/en active Application Filing
- 2013-06-14 PT PT137287587T patent/PT2861229T/en unknown
- 2013-06-14 AU AU2013276451A patent/AU2013276451B2/en active Active
- 2013-06-14 RS RS20201595A patent/RS61288B1/en unknown
- 2013-06-14 ES ES13728758T patent/ES2859758T3/en active Active
- 2013-06-14 CA CA2876540A patent/CA2876540C/en active Active
- 2013-06-14 PL PL13728758T patent/PL2861229T3/en unknown
- 2013-06-14 DK DK13728758.7T patent/DK2861229T3/en active
- 2013-06-14 SG SG11201408251SA patent/SG11201408251SA/en unknown
- 2013-06-14 EP EP20214819.3A patent/EP3831379A1/en active Pending
- 2013-06-14 KR KR20147036089A patent/KR20150021071A/en active Application Filing
- 2013-06-14 LT LTEP13728758.7T patent/LT2861229T/en unknown
- 2013-06-14 CN CN201810359182.XA patent/CN108273064A/en active Pending
- 2013-06-14 EP EP13728758.7A patent/EP2861229B1/en active Active
- 2013-06-14 JP JP2015516627A patent/JP6855165B2/en active Active
- 2013-06-14 US US14/407,780 patent/US10426765B2/en active Active
- 2013-06-14 CN CN201380031622.4A patent/CN104363907A/en active Pending
- 2013-06-14 BR BR112014030835-7A patent/BR112014030835B1/en active IP Right Grant
- 2013-06-14 NZ NZ702297A patent/NZ702297A/en unknown
- 2013-06-14 IN IN10260DEN2014 patent/IN2014DN10260A/en unknown
- 2013-06-14 RU RU2014148239A patent/RU2657797C2/en active
- 2013-06-14 MX MX2014015217A patent/MX370795B/en active IP Right Grant
- 2013-06-14 HU HUE13728758A patent/HUE053359T2/en unknown
- 2013-06-14 SI SI201331842T patent/SI2861229T1/en unknown
- 2013-06-14 KR KR1020207002601A patent/KR102211832B1/en active IP Right Grant
- 2013-06-15 SA SA113340643A patent/SA113340643B1/en unknown
- 2013-06-16 JO JOP/2013/0182A patent/JO3578B1/en active
- 2013-06-17 AR ARP130102127 patent/AR091465A1/en unknown
- 2013-06-17 TW TW102121395A patent/TWI624260B/en active
-
2014
- 2014-12-04 ZA ZA2014/08922A patent/ZA201408922B/en unknown
- 2014-12-05 PH PH12014502744A patent/PH12014502744A1/en unknown
- 2014-12-11 IL IL236205A patent/IL236205B/en active IP Right Grant
-
2015
- 2015-06-17 HK HK15105790.4A patent/HK1204972A1/en unknown
-
2018
- 2018-12-13 JP JP2018233038A patent/JP2019069972A/en active Pending
-
2019
- 2019-09-16 US US16/572,494 patent/US20200009124A1/en active Pending
-
2021
- 2021-01-19 HR HRP20210090TT patent/HRP20210090T1/en unknown
- 2021-03-02 CY CY20211100172T patent/CY1123999T1/en unknown
- 2021-10-15 JP JP2021169322A patent/JP2022017332A/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201408251SA (en) | A pharmaceutical composition containing nicotinic acid and/or nicotinamide and/or tryptophan for positively influencing the intestinal microbiota | |
| SG11201408261UA (en) | Syringe | |
| SG11201906891RA (en) | Methods for the administration of certain vmat2 inhibitors | |
| SG11201805320XA (en) | Materials and methods for treatment of amyotrophic lateral sclerosis and/or frontal temporal lobular degeneration | |
| SG11201408769QA (en) | Methods of reducing the risk of a cardiovascular event in a subject on statin therapy | |
| SG11201407417VA (en) | Encoding and reconstruction of residual data based on support information | |
| SG11201407580YA (en) | Composition comprising two antibodies engineered to have reduced and increased effector function | |
| SG11201804758QA (en) | Aqueous pharmaceutical formulation comprising anti-pd-1 antibody avelumab | |
| SG11201908640TA (en) | Pyrrolidinones and a process to prepare them | |
| SG11201408303WA (en) | Adhesive compositions of propylene-based and ethylene-based polymers | |
| SG11201408385TA (en) | Methods of detecting diseases or conditions | |
| SG11201407747QA (en) | A method and apparatus for facilitating the management of health and security | |
| SG11201408094YA (en) | Neprilysin inhibitors | |
| SG11201408237YA (en) | Compound as wnt signaling inhibitor, composition, and use thereof | |
| SG11201407200TA (en) | Liquid formulation | |
| SG11201901438VA (en) | Solid forms of cenicriviroc mesylate and processes of making solid forms of cenicriviroc mesylate | |
| SG11201906436VA (en) | Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same | |
| SG11201810177VA (en) | Pet-imaging immunomodulators | |
| SG11201806267QA (en) | Organic reactions carried out in aqueous solution in the presence of a hydroxyalkyl(alkyl)cellulose or an alkylcellulose | |
| SG11201406787TA (en) | Rnai-based therapies for cardiomyopathies, muscular dystrophies and laminopathies | |
| SG11201402986RA (en) | Kinase inhibitors | |
| SG11201408641UA (en) | Phenoxyethyl piperidine compounds | |
| SG11201808713YA (en) | Ophthalmic compositions comprising levodopa, an antioxidant and an aqueous carrier | |
| SG11201408509PA (en) | Racecadotril lipid compositions | |
| SG11201407536UA (en) | Topical pharmaceutical compositions comprising terbinafine and urea |